Finally, we demonstrate that NIC-12 suppresses circulating IL-1ß levels in vivo in LPS-challenged mice and inhibits NLRP3 inflammasome activation in primary monocytes from CAPS patients and macrophages expressing various disease-associated NLRP3 mutants with significantly increased potency compared with CRID3. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.